South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug ...

Learn how long you'll likely receive Keytruda infusions, what factors can affect your treatment length, and what to expect ...

Merck (MRK) has been adjusting Keytruda to make it easier to use and to protect the company for after the U.S. patent protection runs out in 2028, Jared Hopkins of The Wall Street Journal reports.

Merck added it expects U.S. sales of Keytruda to further decline upon loss of key patents in 2028. The treatment, approved in 2014, harnesses the body's own immune system to fight cancers with ...

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

The study also showed a statistically significant improvement in major pathological response, a key secondary endpoint, for patients in the keytruda arm compared with adjuvant radiotherapy alone.

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

Merck reported total sales of $64.2B for 2024, with Keytruda contributing $29.5B. Key patents for Keytruda are also reportedly set to expire in 2028. The company has been developing a more easily ...

For patients with unresectable, non-metastatic hepatocellular carcinoma, Lenvima plus Keytruda in combination with TACE improved outcomes. Among patients with unresectable, non-metastatic ...

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human IgG1 ...